Ann: Appendix 4C, page-27

I'm not going to try to make the case that a capital raising will not happen in 20128 but, instead make a few points that could mitigate the circumstances for a capital raise.

First, AXP's product is unique in its market; innovative, less painful, safer, more convenient and gives it's recipient a degree of control over a part of their recovery process at a time when having some of that  control is appreciated. While  sales growth cannot be guaranteed, Aeroform is, for me, a great value proposition.

Have a look at the 10Q from last September....



For the September quarter cost of sales was greater than revenue and operating expenses was $5,323, which equates to $1.8 million per month. Canaccord issued a research report on 6 Aug 2017. It's safe to assume they put it together with AXP Management input. That report stated the long term gross margin to be 75%. At a Sell Price of $2,500 and a gross margin of $1,875 then EBIT break-even comes with a monthly volume of 1,000 units. For me that is not a stretch!

Furthermore it is fallacious to automatically equate a capital raising with negative sentiment. That situation occurs when a company needs cash to continue to develop its value proposition. A capital raise to fund evident strong growth is a good story.   

Cheers